MA31635B1 - Dérivés de 1-oxo-isoindoline-4-carboxamides et de 1-oxo-1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur préparation et leur application en thérapeutique - Google Patents

Dérivés de 1-oxo-isoindoline-4-carboxamides et de 1-oxo-1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur préparation et leur application en thérapeutique

Info

Publication number
MA31635B1
MA31635B1 MA32652A MA32652A MA31635B1 MA 31635 B1 MA31635 B1 MA 31635B1 MA 32652 A MA32652 A MA 32652A MA 32652 A MA32652 A MA 32652A MA 31635 B1 MA31635 B1 MA 31635B1
Authority
MA
Morocco
Prior art keywords
group
alkyl
oxo
cycloalkyl
atom
Prior art date
Application number
MA32652A
Other languages
Arabic (ar)
English (en)
Inventor
Bernard Baudoin
Michel Evers
Arielle Genevois-Borella
Andreas Karlsson
Jean-Luc Malleron
Magali Mathieu
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31635B1 publication Critical patent/MA31635B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne les dérivés de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tétrahydroisoquinoléine-5-carboxamides, de formule générale (i) dans laquelle r1 représente un atome d'hydrogène, un groupe (c1-c6)alkyle, (c3-c7)cycloalkyle (ch2)n-(c1-c6)alcényle, (ch2)n-(c1-c6)alcynyle, (c1-c6)alkyle-z-(c1-c6)alkyle dans lequel z représente un hétéroatome choisi parmi o, n et s(o)m, ou bien r1 représente u groupe coor, s(o)mr, un aryle ou un aralkyle; r2 représente un ou plusieurs groupe choisis parmi un atome d'hydrogène, un atome d'halogène, un groupe (c1-c6)alkyle, (c3- c7)cycloalkyle,.(c1-c6)alcényle, (c1-c6)alcynyle, (c1-c6)alkyle-z-(c1-c6)alky!E, dans lequel z représente un hétéroatome choisi parmi o, n et s(o)m, ou bien r2 représente u groupe halo(c1-c6)alkyle, halo(c1-c6)alcoxy, hydroxy, (c1-c6)alcoxy, nitro, cyano, amino un groupe nr7r8, coor, conr7r8, oco(c1-c6)alkyle, s(o)mnr7r8, un groupe aryle r3 représente un groupe trifluorométhyle; r4 et r5 représentent, indépendamment l'un d l'autre, un atome d'hydrogène, ou bien r4 et r5 forment avec l'atome de carbone qui le porte un cycle saturé contenant de 3 à 6 atomes de carbone et contenant éventuellement de o à 1 hétéroatome choisis parmi o, n ou s; r6 représente un groupe choisi parmi u atome d'hydrogène, un atome d'halogène, un groupe (c1-c6)alkyle, (c3-c7)cycloalkyle (c3-c7)cycloalkyle(c1-c6)alkyle, un groupe halo(c1-c6)alkyle, nitro, amino, un group nr7r8, coor, un groupe nr7(so2)r8, conr7r8, un groupe aryle ou hétérocycle; représente un groupe (c1-c2)alkylène; m représente un nombre entier compris entre o et 2 n représente un nombre entier compris entre 1 et 6. L'invention a également trait à leur procédé de préparation et leur application e thérapeutique comme inhibiteurs de ß-secrétase pour traiter les trouble neurodégénératifs tels qu'alzheimer. I
MA32652A 2007-07-27 2010-02-24 Dérivés de 1-oxo-isoindoline-4-carboxamides et de 1-oxo-1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur préparation et leur application en thérapeutique MA31635B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0705499A FR2919285B1 (fr) 2007-07-27 2007-07-27 Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
PCT/FR2008/001110 WO2009044019A2 (fr) 2007-07-27 2008-07-25 Dérivés de 1-oxo-isoindoline-4-carboxamides et de 1-oxo-1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
MA31635B1 true MA31635B1 (fr) 2010-08-02

Family

ID=39092246

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32652A MA31635B1 (fr) 2007-07-27 2010-02-24 Dérivés de 1-oxo-isoindoline-4-carboxamides et de 1-oxo-1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur préparation et leur application en thérapeutique

Country Status (19)

Country Link
US (1) US8372864B2 (fr)
EP (1) EP2185511A2 (fr)
JP (1) JP5412428B2 (fr)
KR (1) KR20100051830A (fr)
CN (1) CN101790514B (fr)
AU (1) AU2008306763B2 (fr)
BR (1) BRPI0813624A2 (fr)
CA (1) CA2694322A1 (fr)
CO (1) CO6290678A2 (fr)
EA (1) EA201070197A1 (fr)
FR (1) FR2919285B1 (fr)
HK (1) HK1143163A1 (fr)
MA (1) MA31635B1 (fr)
MX (1) MX2010001079A (fr)
MY (1) MY150436A (fr)
NZ (1) NZ582873A (fr)
SG (1) SG183082A1 (fr)
WO (1) WO2009044019A2 (fr)
ZA (1) ZA201000582B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014000267A2 (pt) 2011-07-04 2016-09-20 Bayer Ip Gmbh utilização de isoquinolinonas, isoquinolinedionas, isoquinolinetrionas e dihidroisoquinolinonas substituídas ou, em cada caso, sais das mesmas como agentes ativos contra o stress abiótico em plantas
CN105254554B (zh) * 2014-07-14 2018-01-30 南开大学 一种制备异吲哚啉酮类化合物的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6777896A (en) * 1995-08-25 1997-03-19 E.I. Du Pont De Nemours And Company Bicyclic herbicides
DE10018449A1 (de) 2000-04-14 2001-11-22 Top Caredent Ag Zuerich Vorrichtung zum Darbieten von Gerätschaften der Dentalhygiene
US7176242B2 (en) * 2001-11-08 2007-02-13 Elan Pharmaceuticals, Inc. N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
GB0309221D0 (en) 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
GB0328900D0 (en) 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
US7745470B2 (en) 2005-03-10 2010-06-29 Bristol-Myers Squibb Company Isophthalates as beta-secretase inhibitors
GB0506562D0 (en) 2005-03-31 2005-05-04 Glaxo Group Ltd Novel compounds
NZ582871A (en) * 2007-07-27 2011-09-30 Sanofi Aventis 1,2,3,4-Tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5- tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof
FR2919286A1 (fr) * 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
FR2919285A1 (fr) 2009-01-30
HK1143163A1 (fr) 2010-12-24
US20100197725A1 (en) 2010-08-05
KR20100051830A (ko) 2010-05-18
SG183082A1 (en) 2012-08-30
CN101790514B (zh) 2012-12-19
WO2009044019A2 (fr) 2009-04-09
JP5412428B2 (ja) 2014-02-12
US8372864B2 (en) 2013-02-12
MY150436A (en) 2014-01-30
EP2185511A2 (fr) 2010-05-19
MX2010001079A (es) 2010-03-24
NZ582873A (en) 2012-07-27
CO6290678A2 (es) 2011-06-20
AU2008306763B2 (en) 2013-08-29
WO2009044019A9 (fr) 2010-10-14
BRPI0813624A2 (pt) 2019-09-24
ZA201000582B (en) 2011-04-28
JP2010534641A (ja) 2010-11-11
WO2009044019A3 (fr) 2009-06-18
CA2694322A1 (fr) 2009-04-09
FR2919285B1 (fr) 2012-08-31
EA201070197A1 (ru) 2010-08-30
CN101790514A (zh) 2010-07-28
AU2008306763A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
RU2434865C2 (ru) Аналоги тетрагидрохинолина в качестве мускариновых агонистов
CA2662848C (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
MA31373B1 (fr) Composes amino-heterocycliques
MA27079A1 (fr) Derives 1, 6-naphthyridine et leur utilisation dans le traitement du diabete et de troubles associes
KR970059163A (ko) 할로겐기가 치환된 2-페닐-1, 2-에탄디올 카바메이트 화합물
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
HUP0303281A2 (hu) Benzodiazepinszármazékok, mint GABA A receptor modulátorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
SE0104334D0 (sv) Therapeutic agents
RU2008119842A (ru) Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1
MA31865B1 (fr) Dérivés isoxazolo-pyridine
MA30695B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole -2-carboxamides, leur preparation et leur application en therapeutique.
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
MA30167B1 (fr) Nouveaux composes
TNSN07041A1 (fr) Derives de n-(1 h-indolyl)-i h-indole-2-carboxamides, leur preparation et leur application en therapeutique
MA30315B1 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HUP0105073A2 (hu) 2-Amino-piridin-származékok, ezek alkalmazása gyógyszerként és ezeket tartalmazó gyógyászati készítmények
TW200740827A (en) Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
TW200736251A (en) Aryl-isoxazol-4-yl-imidazole derivatives
NZ336623A (en) 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines for use in the treatment and prevention of disorders of the central nervous system
MA31742B1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
RU2010107603A (ru) Производные n-(2-тиазолил)амида для лечения ожирения, диабетов и сердечно-сосудистых заболеваний
MA31629B1 (fr) Dérivés de 1-0x0-1,2-dihydroisoquinoleine-5-carboxamides et de 4-oxo-3,4-dihydroquinazoline-8-carboxamides, leur préparation et leur application en thérapeutique
TNSN04234A1 (fr) Derives de n-acylaminobenzene comme inhibiteurs selectifs de la monoamine oxydase b